GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QuidelOrtho Corp (NAS:QDEL) » Definitions » Beneish M-Score

QDEL (QuidelOrtho) Beneish M-Score : -2.72 (As of Jul. 13, 2025)


View and export this data going back to 1981. Start your Free Trial

What is QuidelOrtho Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.72 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for QuidelOrtho's Beneish M-Score or its related term are showing as below:

QDEL' s Beneish M-Score Range Over the Past 10 Years
Min: -4.31   Med: -2.44   Max: 1.4
Current: -2.72

During the past 13 years, the highest Beneish M-Score of QuidelOrtho was 1.40. The lowest was -4.31. And the median was -2.44.


QuidelOrtho Beneish M-Score Historical Data

The historical data trend for QuidelOrtho's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QuidelOrtho Beneish M-Score Chart

QuidelOrtho Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 -2.80 -1.46 -2.70 -2.80

QuidelOrtho Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.59 -2.48 -2.64 -2.80 -2.72

Competitive Comparison of QuidelOrtho's Beneish M-Score

For the Medical Devices subindustry, QuidelOrtho's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QuidelOrtho's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, QuidelOrtho's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where QuidelOrtho's Beneish M-Score falls into.


;
;

QuidelOrtho Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of QuidelOrtho for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0098+0.528 * 1.0275+0.404 * 0.9757+0.892 * 0.9658+0.115 * 0.9932
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0133+4.679 * -0.041135-0.327 * 1.0743
=-2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Total Receivables was $437 Mil.
Revenue was 692.8 + 707.8 + 727.1 + 637 = $2,765 Mil.
Gross Profit was 343.3 + 326.1 + 352.3 + 276 = $1,298 Mil.
Total Current Assets was $1,258 Mil.
Total Assets was $6,462 Mil.
Property, Plant and Equipment(Net PPE) was $1,564 Mil.
Depreciation, Depletion and Amortization(DDA) was $446 Mil.
Selling, General, & Admin. Expense(SGA) was $749 Mil.
Total Current Liabilities was $1,047 Mil.
Long-Term Debt & Capital Lease Obligation was $2,269 Mil.
Net Income was -12.7 + -178.4 + -19.9 + -147.7 = $-359 Mil.
Non Operating Income was -15 + -111.4 + -30.7 + -85.1 = $-242 Mil.
Cash Flow from Operations was 65.6 + 63.7 + 117.9 + -97.9 = $149 Mil.
Total Receivables was $448 Mil.
Revenue was 711 + 742.6 + 744 + 665.1 = $2,863 Mil.
Gross Profit was 332.1 + 382.6 + 369.4 + 296.5 = $1,381 Mil.
Total Current Assets was $1,212 Mil.
Total Assets was $6,703 Mil.
Property, Plant and Equipment(Net PPE) was $1,622 Mil.
Depreciation, Depletion and Amortization(DDA) was $458 Mil.
Selling, General, & Admin. Expense(SGA) was $766 Mil.
Total Current Liabilities was $780 Mil.
Long-Term Debt & Capital Lease Obligation was $2,423 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(437 / 2764.7) / (448.1 / 2862.7)
=0.158064 / 0.156531
=1.0098

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1380.6 / 2862.7) / (1297.7 / 2764.7)
=0.482272 / 0.469382
=1.0275

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1258.2 + 1564.4) / 6461.6) / (1 - (1212.4 + 1621.8) / 6703.3)
=0.563173 / 0.577193
=0.9757

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2764.7 / 2862.7
=0.9658

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(457.9 / (457.9 + 1621.8)) / (445.6 / (445.6 + 1564.4))
=0.220176 / 0.221692
=0.9932

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(749.1 / 2764.7) / (765.5 / 2862.7)
=0.270952 / 0.267405
=1.0133

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2269.2 + 1047.2) / 6461.6) / ((2422.8 + 779.8) / 6703.3)
=0.513247 / 0.477765
=1.0743

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-358.7 - -242.2 - 149.3) / 6461.6
=-0.041135

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

QuidelOrtho has a M-score of -2.72 suggests that the company is unlikely to be a manipulator.


QuidelOrtho Beneish M-Score Related Terms

Thank you for viewing the detailed overview of QuidelOrtho's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


QuidelOrtho Business Description

Traded in Other Exchanges
Address
9975 Summers Ridge Road, San Diego, CA, USA, 92121
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Executives
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Joseph M Busky officer: Chief Financial Officer 1717 DEERFIELD ROAD, DEERFIELD IL 60015
Louise Brandy officer: SVP, Chief Information Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Patrick Klein officer: Chief Administrative Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Tc Group Vi Cayman, L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Christopher M Smith director 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Douglas C Bryant director, officer: Chairman & CEO C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Michelle A. Hodges officer: SVP, General Counsel 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Wilkins Joseph D Jr. director 82414 PUCCINI DRIVE, INDIO CA 92203
Robert Joseph Bujarski officer: See Remarks C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen H. Wise director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tamara A. Ranalli officer: SVP, Molecular Bus. Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Robert R. Schmidt director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Kenneth F Buechler director
Werner Kroll officer: SVP, Research and Development 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130